Diabetic neuropathic pain (DNP) is complex and refractory. Commonly used calcium channel blockers (CCBs) can be divided into L type and T type. T type CCB mibefradil can alleviate DNP. However, the role of a combined application of L type and T type CCBs in DNP has not been reported. Thirty-six rats were used to establish a type I DNP model using streptozotocin (STZ), and were equally divided into four groups, including DNP group, mibefradil group, verapamil group, and mibefradil and verapamil group. Paw withdrawal mechanical threshold (PWMT) was evaluated by the von Frey method. Paw withdrawal latency (PWL) was determined by thermal radiation. PKC. expression in cornu dorsale medullae spinalis was detected by real-time PCR and Western blot. Inflammatory cytokines TNF-alpha and IL-2 levels were tested by ELISA. Mibefradil and verapamil reduced PWMT and PWL values, downregulated PKC. expression, and inhibited TNF-alpha and IL-2 secretion (P<0.05). The combined treatment group demonstrated stronger analgesic effects than mibefradil or verapamil alone group (P<0.05). Mibefradil and verapamil combined application can alleviate DNP by inhibiting inflammation and reducing PKC. expression which showed better effects than drug single application.